FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

wasnington, D.C. 20549	
STATEMENT OF CHANGES IN BENEFICIAL OWNERSH	ΗP

D O 00E40	
on, D.C. 20549	MB APPROVAL
	 IVID ALL TOVAL

OMB Number: 3235-0287 Estimated average burden

Check this box if no longer subject to Section 16. Form 4 or Form 5

780 THIRD AVENUE, 37TH FLOOR

NY

(State)

10017

(Zip)

(Street) **NEW YORK**

(City)

	ions may conti tion 1(b).	nue. See		File					(a) of the Se				1934			hours	s per re	sponse:	0.5	
Name and Address of Reporting Person* 2. Issue						or Section 30(h) of the Investment Company Act of 1940 Issuer Name and Ticker or Trading Symbol Aclaris Therapeutics, Inc. [ACRS]									Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner					
(Last) (First) (Middle) 780 THIRD AVENUE, 37TH FLOOR						3. Date of Earliest Transaction (Month/Day/Year) 01/11/2019									Officer (give title Other (speci below) below)				(specify	
(Street) NEW YORK NY 10017				4. If	f Ame	ndmen	t, Date	e of Original	Filed	I (Month/D	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Formal Filed by More than One Reporting									
(City)	(S	tate)	(Zip)										Perso	n						
		Tab	le I - No	n-Deriv	ative	Se	curiti	es A	cquired,	Dis	posed	of, or Be	enefi	cially	Owned	k				
Date			Date	nsaction h/Day/Year)		2A. Deemed Execution Date if any (Month/Day/Yea		Code (Insti				4 and Securitie Benefici Owned F		es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)			
									Code	v	Amount	Amount (A) or (D)		ce	Reported Transaction(s) (Instr. 3 and 4)				(111511.4)	
Common	Stock														4,48	1,788		I	Through Deerfield Partners, L.P. ⁽¹⁾⁽²⁾	
Common	Stock														1,41	1,628		I	Through Deerfield Special Situations Fund, L.P.(1)(2)	
		Т							quired, E						Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/Da	ed n Date,	4. Transa	nsaction of Ex							d Amo ies g Secur	8. Price of Derivative Security				10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisab		xpiration ate	Title	Amor or Numl of Share	ber						
Cash- Settled Total Return Swap ⁽³⁾	\$ 7	01/11/2019			J/K		1 ⁽³⁾		(3)	0	1/19/2022	Common Stock	1,8	51	(3)	1		I	Through Deerfield Partners, L.P. ⁽¹⁾⁽²⁾	
Cash- Settled Total Return Swap ⁽⁴⁾	\$6.969 ⁽⁵⁾	01/14/2019			J/K		1 ⁽⁴⁾		(4)	0	1/19/2022	Common Stock	61,7	'89	(4)	1		I	Through Deerfield Partners, L.P. ⁽¹⁾⁽²⁾	
Cash- Settled Total Return Swap ⁽⁶⁾	\$6.931 ⁽⁷⁾	01/15/2019			J/K		1 ⁽⁶⁾		(6)	0	1/19/2022	Common Stock	48,2	:54	(6)	1		I	Through Deerfield Partners, L.P. ⁽¹⁾⁽²⁾	
	nd Address of James E	Reporting Person*					•	•	,			,						,	1	
(Last)		(First)	(Mide	dle)																

ı							
1. Name and Address of Reporting Person* Deerfield Mgmt L.P.							
(Last)	(First)	(Middle)					
780 THIRD AVEN		(,					
37TH FLOOR	02						
(Street)							
NEW YORK	NY	10017					
(City)	(State)	(Zip)					
1. Name and Address of Reporting Person* DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)							
(Last)	(First)	(Middle)					
780 THIRD AVEN		(Middle)					
700 TIIKD AVEN	OE, 37 III PLOOK						
(Street)							
NEW YORK	NY	10017					
(City)	(State)	(Zip)					
1. Name and Address of Reporting Person* <u>Deerfield Special Situations Fund, L.P.</u>							
(Last)	(Eiret)	(Middle)					
(Last)	(First)	(Middle)					
780 3RD AVENUE							
37TH FLOOR							
(Street)							
NEW YORK	NY	10017					
(City)	(State)	(Zip)					
Name and Address of Reporting Person*							
	ARTNERS, L.P.						
(Last)	(First)	(Middle)					
780 THIRD AVEN		,					
37TH FLOOR							
(Street)							
NEW YORK	NY	10017					
(City)	(State)	(Zip)					

Explanation of Responses:

- 1. This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). Deerfield Mgmt, L.P. is the general partner of Deerfield Partners, L.P. ("Deerfield Partners") and Deerfield Special Situations Fund, L.P. (collectively with Deerfield Partners, the "Funds"). Deerfield Management Company, L.P. is the investment manager of the Funds. James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt, L.P. and Deerfield Management Company, L.P.
- 2. In accordance with Instruction 4(b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
- 3. On January 11, 2019, Deerfield Partners entered into a cash-settled total return swap agreement with an unaffiliated third party financial institution, which provides Deerfield Partners with economic exposure to an aggregate of 1,851 notional shares. The swap agreement provides Deerfield Partners with economic results that are comparable to the economic results of ownership of, based on the applicable reference price, but does not provide Deerfield Partners with the power to vote or direct the voting of, or dispose of or direct the disposition of, the shares of common stock that are the subject of such swap agreement.
- 4. On January 14, 2019, Deerfield Partners entered into a cash-settled total return swap agreement with an unaffiliated third party financial institution, which provides Deerfield Partners with economic exposure to an aggregate of 61,789 notional shares. The swap agreement provides Deerfield Partners with economic results that are comparable to the economic results of ownership of, based on the applicable reference prices, but does not provide Deerfield Partners with the power to vote or direct the voting of, or dispose of or direct the disposition of, the shares of common stock that are the subject of such swap agreement.
- 5. The price reported in Column 2 represents a weighted average reference price associated with the swap agreement. The reference prices applicable to the 61,789 notional shares subject to the swap agreement reported herein range from \$6.85 to \$7.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of notional shares subject to each separate reference price within the ranges set forth in footnotes (5) and (7) of this Form 4.
- 6. On January 15, 2019, Deerfield Partners entered into a cash-settled total return swap agreement with an unaffiliated third party financial institution, which provides Deerfield Partners with economic exposure to an aggregate of 48,254 notional shares. The swap agreement provides Deerfield Partners with economic results that are comparable to the economic results of ownership of, based on the applicable reference prices, but does not provide Deerfield Partners with the power to vote or direct the voting of, or dispose of or direct the disposition of, the shares of common stock that are the subject of such swap agreement.
- 7. The price reported in Column 2 represents a weighted average reference price associated with the swap agreement. The reference prices applicable to the 48,254 notional shares subject to the swap agreement reported herein range from \$6.79 to \$7.00, inclusive.

Remarks:

Jonathan Isler, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 3 with regard to Proteon Therapeutics, Inc. filed with the Securities and Exchange Commission on August 4, 2017 by Deerfield Special Situations Fund, L.P., Deerfield Partners, L.P., Deerfield International Master Fund, L.P., Deerfield Private Design Fund III, L.P., Deerfield Mgmt IV, L.P., Deerfield M

Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Joint Filer Information

Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Names:

Deerfield Partners, L.P. and Deerfield Special Situations Fund, L.P.

Address: 780 Third Avenue, 37th Floor

New York, NY 10017

Designated Filer: James E. Flynn

Issuer and Ticker Symbol: Aclaris Therapeutics, Inc. [ACRS]

Date of Earliest Transaction

January 11, 2019

Required To be Reported:

The undersigned, Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P. and Deerfield Special Situations Fund, L.P. are jointly filing the attached Statement of Changes in Beneficial Ownership on Form 4 with James E. Flynn with respect to the beneficial ownership of securities of Aclaris Therapeutics, Inc.

Signatures:

DEERFIELD MGMT, L.P.

By: J.E. Flynn Capital, LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

DEERFIELD MANAGEMENT COMPANY, L.P.

By: Flynn Management LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

DEERFIELD SPECIAL SITUATIONS FUND, L.P.

By: Deerfield Mgmt, L.P., General Partner By: J.E. Flynn Capital, LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

DEERFIELD PARTNERS, L.P.

By: Deerfield Mgmt, L.P., General Partner By: J.E. Flynn Capital, LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact